Safe Fertility Group PCL

Safe Fertility Group PCL maintains a strong liquidity position with a current ratio of 16.69, indicating a high ability to meet short-term obligations. However, the company has negative net cash after subtracting total debt, which introduces a medium liquidity risk. The debt-to-equity ratio is 0.04, suggesting a conservative capital structure with minimal leverage. The company's profitability is reflected in a return on equity of 7.64% and a return on assets of 6.82%, which are key metrics for assessing performance in the healthcare services industry. These figures indicate that the company is generating reasonable returns relative to its equity and asset base. Safe Fertility Group PCL operates through three segments: Obstetrics and Gynecology Hospital, Medical Laboratory, and Cosmetic Dermatology. The company's geographic exposure is primarily concentrated in Thailand, with no significant international operations disclosed in the available data. The company's growth trajectory is supported by a positive outlook for the current fiscal year, with revenue expected to increase. The company's capital expenditure of -47.58 million THB indicates a reduction in investment in physical assets, which may reflect a shift in strategic focus or a response to market conditions. The risk assessment for Safe Fertility Group PCL indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could affect its ability to fund operations without external financing. However, the low dilution risk suggests that the company is not likely to issue additional shares in the near term, preserving shareholder value. Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company's focus remains on its core services in obstetrics, gynecology, and cosmetic dermatology, with no major new initiatives disclosed in the latest financial reports.